Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin for Systemic Inflammation in HIV-Positive Prediabetic Patients
NCT03774108Phase 4Unknown
- Sponsor
- Hospital Civil de Guadalajara
- Start
- Dec 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of liquid metformin (Aspargo Labs) in human immunodeficiency virus type 1 infection (HIV-1) and prediabetes (2 arms), sponsored by Hospital Civil de Guadalajara. Primary endpoint: Quantification of proinflammatory cytokines serum levels at 8 weeks. Status: unknown.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)prediabetes
Beyond the preview
Go deeper on NCT03774108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03774108.